The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

Juno Therapeutics, a subsidiary of Bristol Myers ( BMY) Squibb, was granted FDA orphan designation for its treatment of ...

Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

It can be a real pain in the neck. Rheumatoid arthritis, or RA, is an autoimmune disease in which the body mistakenly attacks ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR ...

New genetic evidence links higher BMI and IBD to hidradenitis suppurativa risk, while smoking remains unclear. Read more.

Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...

基于以上发现，杨骥教授团队构建了一个全新的理论框架，首次解释了系统性硬化症与硬斑病在纤维化发生部位与机制上的差异，初步回答了硬斑病不会向系统性硬化症转化的原因，为两类硬皮病的差异化治疗提供更清晰的方向。

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.